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ABSTRACT
End-organ damage is common in patients with sickle cell disease (SCD) thereby limiting the use of allogeneic
stem cell transplantation (SCT).We report the outcome of 2 adult SCD patients, 1 with end-stage renal disease
(ESRD), who underwent fludarabine-based nonmyeloablative SCT from HLA-identical matched siblings. To
prevent fludarabine toxicity, the patient with ESRD underwent aggressive dialysis following adjusted fludara-
bine dosing. Pharmacokinetics of the fludarabine metabolite F-Ara-A was studied on the patient with ESRD
and 2 additional patients with normal renal function. Both patients with SCD achieved full donor erythroid
chimerism, have normal blood counts, and are on no immunosuppressive medications. With a 20% dose
reduction followed by daily dialysis, we achieved fludarabine drug exposure that is nearly identical to that
achieved in patients with normal renal function. We conclude that fludarabine-based nonmyeloablative allo-
geneic SCT for adult patients with SCD is feasible, even in the setting of ESRD.
© 2007 American Society for Blood and Marrow Transplantation
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INTRODUCTION
Allogeneic stem cell transplantation (SCT) cures
patients with sickle cell disease (SCD); however, the
risk/beneﬁt considerations are complex [1-3]. As pa-
tients age, SCD-related comorbidities increase. This
magniﬁes the importance of a nonmyeloablative SCT
approach that is less likely to result in graft-versus-
host disease (GVHD), but reliable in providing robust
donor stem cell engraftment. Published reports of
nonmyeloablative SCT for SCD have conﬁrmed im-
proved safety, but the majority of such transplants
were unsuccessful because of graft failure [4,5].
The purine analog ﬂudarabine is a critical compo-
nent of nearly all nonmyeloablative SCT preparative
regimens. Because up to 60% of the active metabolite14222-ﬂuoro-ara-A (F-Ara-A) is cleared by the kidneys, use
in patients with renal insufﬁciency or renal failure is
hazardous. We report the outcome of 2 adult patients
with SCD, 1 with end-stage renal disease, who under-
went nonmyeloablative allogeneic SCT using a ﬂu-
darabine-containing preparative regimen. We per-
formed a comparison of the pharmacokinetics of
ﬂudarabine in the context of renal failure and normal
renal function.
PATIENTS, MATERIALS, AND METHODS
Patients
The patients, both with homozygous HgbS, signed
the informed consent for participation in an institutional
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eloablative allogeneic stem cell transplantation (SCT)
for treatment of patients with sickle cell disease
(SCD). The protocol is part of the NHLBI-sponsored
Comprehensive Sickle Cell Centers program. Patient
#1 is a 21-year-old male with a history of frequent
painful episodes, and patient #2 is a 27-year-old with
dialysis-dependent end-stage renal disease following
failure of a kidney graft from his matched sibling, as
well as red cell aplasia and transfusion-associated iron
overload. Fludarabine pharmacokinetics assessment
was performed in patient #2, and in 2 female patients
with hematologic malignancies and normal renal
function (creatinine clearance calculated by Cock-
croft-Gault formula 65 mL/min and 71 mL/min, re-
spectively).
Treatment Plan
The patients underwent pretransplant exchange
transfusion to achieve HgbA 50%. Conditioning
consisted of 200 cGy total-body irradiation (TBI) fol-
lowed by ﬂudarabine (patient #1: 30 mg/m2, patient
#2: 24 mg/m2) and cyclophosphamide 500 mg/m2,
both given daily for 4 days, and alemtuzumab 100 mg,
given in divided doses over 5 days. The ﬂudarabine
dose of 24 mg/m2 represents a dose reduction of 20%,
which was based on the limited available published
experience with ﬂudarabine in the setting of renal
failure [6]. Mycophenolate mofetil (MMF) 2 g/day was
given for 100 days following transplantation. Patients #1
and #2 each received a granulocyte-colony stimulating
factor (G-CSF) mobilized peripheral blood stem cell
(PBSC) graft from an HLA-identical sibling contain-
ing 21  106 and 19  106 CD34 cells/kg, respec-
tively. The donor for patient #2 demonstrated 43%
HgbS consistent with SCD trait. The graft was incu-
bated with alemtuzumab, 10 mg/150 cc “in the bag”
for 30 minutes at 37°C prior to infusion. Patient #2
underwent 6 hours of conventional hemodialysis using
an F200 dialyzer, 12 hours after each ﬂudarabine dose.
Donor chimerism was determined by quantitative
PCR ampliﬁcation of informative microsatellites us-
ing DNA isolated from peripheral blood CD3 and
CD15 cells. Erythroid chimerism was determined by
hemoglobin electrophoresis.
Pharmacokinetic Studies
Plasma samples from patient #2 and 2 additional
non-SCD patients with normal renal function under-
going stem cell transplantation using the same che-
motherapy preparative regimen (but without TBI)
were collected over 24 hours after doses 1 and 4 of
ﬂudarabine. F-Ara-A was measured by a LC/MS/MS
assay that was developed and validated at the Duke
Pharmacokinetics laboratory (data not published).Lymphocyte Subset Analysis
Lymphocyte subsets (T cell and natural killer
[NK] cells) were enumerated using 2-color multipa-
rameter ﬂow cytometry. Peripheral blood mononu-
clear cells were prepared by Ficoll separation of
freshly drawn, heparinized whole blood. Samples were
cryopreserved at 70°C and processed in bulk. Cells
were stained with ﬂuorescence-labeled monoclonal
antibodies (mAb) with speciﬁcity to anti-CD2, -CD3,
-CD4, -CD8, -CD16, and -CD56. Analysis was per-
formed on a FACScan ﬂow cytometer (Becton Dick-
inson, San Jose, CA).
RESULTS AND DISCUSSION
Treatment-Related Toxicity
Both patients tolerated the conditioning regimen
without unanticipated complications. Patient #1 never
required hospital admission. Patient #2 was hospitalized
for administration of the conditioning regimen to facil-
itate intensive dialysis. The peritransplant hematologic
parameters are demonstrated in Figure 1A and C. Pa-
tients #1 and #2 were neutropenic (absolute neutrophil
count 500) for 3 and 12 days, respectively. Patient #1
platelet nadir was 141,000. Patient #2 required 6 platelet
transfusions to maintain the protocol-mandated mini-
mum count of 50,000.
Neither patient had adverse drug effects attribut-
able to ﬂudarabine toxicity. Neither patient experi-
enced aGVHD, and with a median follow-up of 20
months, neither has experienced cGVHD. However,
4 months posttransplant, patient #2 developed symp-
tomatic heart failure. His echocardiogram, which was
normal prior to transplantation, demonstrated mod-
erate left ventricular dilatation, a small pericardial
effusion and an ejection fraction of 35%. Although the
ejection fraction dropped to a low of 20%, a cardiac
MUGA scan performed 15 months posttransplant re-
vealed signiﬁcant recovery to 38%.
Hematopoietic Recovery, Immune Recovery,
and Engraftment
Myeloid and erythroid chimerism, along with he-
matocrit, are demonstrated in Figure 1B and D. Both
patients have stable donor T cell (CD3) chimerism.
At 18 months of follow-up, patient #1 has 85% donor
T cells and at 12 months of follow-up, patient #2 has
58% donor T cells. By 3 months following transplan-
tation, both patients achieved full donor erythroid
chimerism as demonstrated by a hemoglobin electro-
phoresis pattern that mirrored that of their stem cell
donor. This resulted in normalization of the hemato-
crit levels. Patient #2 began therapeutic phlebotomy at
90 days posttransplant to address iron overload.
At 1 year post-transplant, both patients had CD4
and CD8 counts approaching normal limits [7] (Fig-
M. E. Horwitz et al.1424Figure 1. Hematopoietic recovery and donor/recipient chimerism following transplantation. A, Sickle cell disease patient #1 white blood cell
count and platelet count during the peritransplant period. B, Sickle cell disease patient #1 donor/recipient myeloid and erythroid (as measured
by percent hemoglobin A) chimerism and hematocrit following stem cell transplantation. C, Sickle cell disease patient #2 white blood cell count
and platelet count during the peritransplant period. D, Sickle cell disease patient #2 donor/recipient myeloid and erythroid (as measured by
percent hemoglobin A) chimerism and hematocrit following stem cell transplantation. Of note, the donor for patient #2 has sickle cell trait.
Elevated pretransplantation hemoglobin A reﬂects protocol-mandated exchange transfusions.ure 2). At 2 years of follow-up, patient #1 had normal
numbers of T cells and B cells (data not shown).
Interestingly, absolute numbers of NK cells were per-
sistently low in both patients for the duration of the
follow-up period (Figure 2).
F-ara-A Pharmacokinetics
F-ara-A pharmacokinetics in the SCD patient
with renal failure was compared to 2 patients with
normal renal function (Figure 3). With a 20% ﬂu-
darabine dose reduction and once daily intensive
dialysis, we achieved nearly identical drug exposure
(area under the curve 4093 mg · h/L versus mean
4010 mg · h/L). As a consequence of the 20% dose
reduction, the maximum concentration of F-ara-A
was lower in the renal failure patient, but this was
compensated for by lower drug clearance (5.3 l/h
versus mean 6.4 l/h).DISCUSSION
Recently described clinical and laboratory charac-
teristics such as pulmonary hypertension, renal insuf-
ﬁciency, and leukocytosis, along with the intensity of
hemolysis allow for the identiﬁcation of SCD patients
who are destined to succumb to complications before
the median survival of approximately 40-50 years
[8-10]. These are the patients that should be targeted
for a safe and reliable allogeneic stem cell transplant
approach. The ideal approach would be one that com-
bines a suitably matched sibling or possibly unrelated
donor with a nonmyeloablative preparative regimen
that incorporates T cell depletion to protect against
GVHD. Of the 15 SCD patients reported in the
literature that have undergone nonmyeloablative
SCT, only 6 have engrafted [4,5,11-14]. Of these, 3
developed aGVDH or cGVHD. We report 2 consec-
utive adult patients who were successfully transplanted
with an alemtuzumab-containing nonmyeloablative
regimen that has been shown to signiﬁcantly reduce
the risk of GVHD [15-17]. Despite the use of Ale-
mtuzumab, which is known to compromise posttrans-
plant immune recovery, we observed robust immune
recovery in both transplant recipients. This is attrib-
utable to their relatively young age, lack of pretrans-
plant chemotherapy exposure, and the absence of
GVHD.
There is limited published experience with the use of
ﬂudarabine in the setting of renal impairment [6]. Severe
Figure 2. T cell and NK cell recovery following stem cell trans-
plantation. Pretransplant and 6-month posttransplant data points
are not available for patient #2.
Stem Cell Transplantation for Sickle Cell Diseaseneurotoxicity is of primary concern in this patient pop-
ulation given the potential for excessively high levels of
F-ara-A [18]. The approach employed in our case was
based on that of Kielstein et al. [19], who reported
F-ara-A pharmacokinetic data in an anuric patient given
ﬂudarabine for treatment of chronic lymphocytic leuke-
mia (CLL). Using a 20% dose reduction of ﬂudarabine
and intensive daily dialysis, this regimen can be applied
to patients with end stage renal disease. Although it is
likely that cyclophosphamide toxicity is the primary
cause of the patient’s cardiac pathology [20], it is possible
that cardiac iron deposition (pretransplant ferritin, 7200
ng/mL) was a contributing factor.
The more severe bone marrow suppression ob-
served in the patient with renal failure suggests the
possible need for cyclophosphamide dose reduction in
such patients. However, further experience is needed
for this observation to be conﬁrmed.
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Figure 3. F-ara-A pharmacokinetics in a patient with dialysis-
dependent renal failure and sickle cell disease and two patients with
normal renal function.
1425
M. E. Horwitz et al.1426REFERENCES
1. Walters MC, Patience M, Leisenring W, et al. Bone marrow
transplantation for sickle cell disease [see comments]. N Engl
J Med. 1996;335:369-376.
2. Panepinto JA, Walters MC, Carreras J, et al. Matched-related
donor transplantation for sickle cell disease: report from the
Center for International Blood and Transplant Research. Br J
Haematol. 2007;137:479-485.
3. Walters MC, Storb R, Patience M, et al. Impact of bone
marrow transplantation for symptomatic sickle cell disease:
an interim report. Multicenter investigation of bone marrow
transplantation for sickle cell disease. Blood. 2000;95:1918-
1924.
4. Iannone R, Casella JF, Fuchs EJ, et al. Results of minimally
toxic nonmyeloablative transplantation in patients with sickle
cell anemia and beta-thalassemia. Biol Blood Marrow Transplant.
2003;9:519-528.
5. Horan JT, Liesveld JL, Fenton P, Blumberg N, Walters MC.
Hematopoietic stem cell transplantation for multiply transfused
patients with sickle cell disease and thalassemia after low-dose
total body irradiation, ﬂudarabine, and rabbit anti-thymocyte
globulin. Bone Marrow Transplant. 2005;35:171-177.
6. Lichtman SM, Etcubanas E, Budman DR, et al. The pharma-
cokinetics and pharmacodynamics of ﬂudarabine phosphate in
patients with renal impairment: a prospective dose adjustment
study. Cancer Invest. 2002;20:904-913.
7. Storek J, Dawson MA, Maloney DG. Normal T, B, and NK cell
counts in healthy donors at 1 year after blood stem cell har-
vesting. Blood. 2000;95:2993-2994.
8. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hyper-
tension as a risk factor for death in patients with sickle cell
disease. N Engl J Med. 2004;350:886-895.
9. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell
disease. Life expectancy and risk factors for early death. N Engl
J Med. 1994;330:1639-1644.
10. Sebastiani P, Nolan V, Clinton B, et al. A network model to
predict the risk of death in sickle cell disease. Blood. 2007.11. van Besien K, Bartholomew A, Stock W, et al. Fludarabine-
based conditioning for allogeneic transplantation in adults
with sickle cell disease. Bone Marrow Transplant. 2000;26:
445-449.
12. van Besien K, Stock W, Smith S, et al. Allogeneic stem cell
transplantation with ﬂudarabine, melphalan, and campath con-
ditioning for adults with advanced sickle cell disease. Blood.
2002;100:430b.
13. Krishnamurti L, Blazar BR, Wagner JE. Bone marrow trans-
plantation without myeloablation for sickle cell disease. N Engl
J Med. 2001;344:68.
14. Schleuning M, Stoetzer O, Waterhouse C, Schlemmer M,
Ledderose G, Kolb HJ. Hematopoietic stem cell transplanta-
tion after reduced-intensity conditioning as treatment of sickle
cell disease. Exp Hematol. 2002;30:7-10.
15. Kottaridis PD, Milligan DW, Chopra R, et al. In vivo
CAMPATH-1H prevents graft-versus-host disease following
nonmyeloablative stem cell transplantation. Blood. 2000;96:2419-
2425.
16. Rizzieri DA, Koh LP, Long GD, et al. Partially matched,
nonmyeloablative allogeneic transplantation: clinical outcomes
and immune reconstitution. J Clin Oncol. 2007;25:690-697.
17. Tauro S, Craddock C, Peggs K, et al. Allogeneic stem-cell
transplantation using a reduced-intensity conditioning regimen
has the capacity to produce durable remissions and long-term
disease-free survival in patients with high-risk acute myeloid
leukemia and myelodysplasia. J Clin Oncol. 2005;23:9387-9393.
18. Cheson BD, Vena DA, Foss FM, Sorensen JM. Neurotoxicity
of purine analogs: a review. J Clin Oncol. 1994;12:2216-2228.
19. Kielstein JT, Stadler M, Czock D, Keller F, Hertenstein B, Rad-
ermacher J. Dialysate concentration and pharmacokinetics of 2F-
Ara-A in a patient with acute renal failure. Eur J Haematol. 2005;
74:533-534.
20. Cazin B, Gorin NC, Laporte JP, et al. Cardiac complications
after bone marrow transplantation. A report on a series of 63
consecutive transplantations. Cancer. 1986;57:2061-2069.
